Buys C H, Bouma J M, Gruber M, Wisse E
Naunyn Schmiedebergs Arch Pharmacol. 1978 Sep;304(2):183-90. doi: 10.1007/BF00495555.
Isolated livers of rats injected with saline or with suramin (250 mg per kg body weight) 24h previously were perfused with a medium containing radioactively labeled formaldehyde-treated albumin. Suramin-loaded livers released breakdown products at a much lower rate than controls and contained about the double amount of undigested radioactive protein up to about 3 h after the start of the perfusion. These results show that inhibition of proteolysis by suramin as reported previously (Davies et al., 1971; Buys et al., 1973) is not caused by binding of the drug to the substrate in the bloodstream. Electron micrographs of liver sections of suramin-treated rats showed that lysosomes of sinusoidal cells resembled those seen in certain lysosomal storage diseases. The effect of suramin on lysosomal enzymes was studied in vitro. When used at a concentration corresponding to the putative concentration in lysosomes in vivo, the drug inhibited the lysosomal endopeptidases cathepsin Bl and D as well as acid phosphatase. Inhibition of acid phosphatase by suramin in vivo could also be demonstrated by histochemical methods. These results suggest that the observed storage phenomena may be mainly caused by inhibition of lysosomal enzymes.
将生理盐水或24小时前注射过苏拉明(每千克体重250毫克)的大鼠的离体肝脏,用含有放射性标记的甲醛处理过的白蛋白的培养基进行灌注。负载苏拉明的肝脏释放分解产物的速率比对照低得多,并且在灌注开始后约3小时内,未消化的放射性蛋白质含量约为对照的两倍。这些结果表明,如先前报道(戴维斯等人,1971年;布伊斯等人,1973年),苏拉明对蛋白水解的抑制作用并非由药物与血液中的底物结合所致。苏拉明处理的大鼠肝脏切片的电子显微镜照片显示,窦状细胞的溶酶体类似于某些溶酶体贮积病中所见的溶酶体。在体外研究了苏拉明对溶酶体酶的作用。当以与体内溶酶体中假定浓度相对应的浓度使用时,该药物抑制溶酶体内肽酶组织蛋白酶B1和D以及酸性磷酸酶。苏拉明在体内对酸性磷酸酶的抑制作用也可以通过组织化学方法证实。这些结果表明,观察到的贮积现象可能主要是由溶酶体酶的抑制引起的。